// App-Quantinova.ai

PO1004 : Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

Researchers

Presenter

  • Kang Amy

Principal Investigators

  • L Heerspink HiddoJan

  • Di Tanna Gian Luca

  • Neal Bruce

  • Zhang Hong

  • Hockham Carinna

  • Agarwal Rajiv

  • Bakris GeorgeL

  • Charytan DavidM

  • de Zeeuw Dick

  • Greene Tom

  • Levin Adeera

  • Pollock CarolA

  • Wheeler DavidC

  • Zinman Bernard

  • Mahaffey KennethW

  • Perkovic Vlado

  • Jardine MegJ

Medical Centers

  • The George Institute for Global Health, Sydney, NewSouth Wales, Australia

  • Rijksuniversiteit Groningen, Groningen, Netherlands

  • IU School of Medicine, Indianapolis, Indiana, United States

  • University Illinois Chicago, Chicago, Illinois, United States

  • NYU Langone Health New York City New York United States

  • University of Utah, Salt Lake City, Utah, United States

  • The University of British Columbia Faculty of Medicine Vancouver British Columbia Canada

  • University of Sydney - Camperdown and Darlington Campus Burkitt-Ford Library Sydney New South Wales Australia

  • Kings College London, London, United Kingdom

  • The Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada

  • Stanford University Medical Center, Stanford, California, United States

Locations

  • Australia

  • Netherlands

  • China

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Urology

Disease

  • Urinary tract infections

  • Chronic kidney disease

  • Diabetes

  • Type 2 diabetes mellitus

  • Renal disease

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • Canagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved